# Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease.

> **NIH NIH N01** · UNIVERSITY OF MONTANA · 2022 · $1,000,000

## Abstract

Lyme disease, caused by the bite of Borrelia burgdorferi-infect Ixodes ticks, affects close to half a million Americans each year and can cause serious, long term, chronic health issues such as Lyme arthritis, Lyme encephalopathy, or skin disorders. No human vaccine is currently available and the contractor proposes to develop a novel subunit Lyme disease vaccine adjuvanted with a combination adjuvant composed of two synthetic TLR agonists (TLR4 and TLR7/8).

## Key facts

- **NIH application ID:** 10667372
- **Project number:** 272201800048C-P00011-9999-1
- **Recipient organization:** UNIVERSITY OF MONTANA
- **Principal Investigator:** JAY EVANS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,000,000
- **Award type:** —
- **Project period:** 2018-09-30 → 2024-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10667372

## Citation

> US National Institutes of Health, RePORTER application 10667372, Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease. (272201800048C-P00011-9999-1). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10667372. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*